Bruker buys mAb and immunoassay supplier InVivo

By Dan Stanton

- Last updated on GMT

Image: iStock/extender01
Image: iStock/extender01

Related tags Monoclonal antibodies

Bruker has bolstered its molecular biologics and mass spectrometric offering through the acquisition of contract manufacturing organisation (CMO) InVivo Biotech.

The deal – financial details of which were not divulged – gives scientific instrumentation firm Bruker Corporation mammalian cell culture and protein production capabilities, allowing the firm to supply monoclonal antibodies to CMO customers.

InVivo will continue to operate under its existing name and management team, but the deal allows Berlin, Germany-based Bruker to offer purified mAbs derived from a collection of more than 3,000 different hybridoma clones producing human, rat or mouse monoclonals to its CMO customers, as well as a proprietary media for serum-free cultivation.

The company will also increase its portfolio of immunoassay components and research kits through the addition of nearby InVivo.

“The acquisition of InVivo is part of our strategy to expand our microbiology assay menu for our mass spectrometric MALDI Biotyper platform,”​ Bruker spokesman Winfried Busch told

The platform offers drugmakers molecular identification and taxonomical classification of microorganisms and can be used in environmental and pharmaceutical analysis within the preclinical space.

The addition of InVivo will also “support our activities in translational pathology research with the MALDI Tissuetyper, a system solution for the label free detection of protein biomarkers in tissue sections,”​ Busch added.

InVivo Biotech’s founders, Wolfgang Weglöhner and Siegmund Karasch, added in a statement the deal brings: “Expanded opportunities for our business using the global commercial infrastructure of Bruker, particularly for microbiology and pathology.

“With our molecular biology core products and CMO services, we anticipate significant growth and expansion opportunities."

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us


View more